BR112017016347A2 - ?novas composições e métodos para o tratamento e/ou prevenção de doença pulmonar obstrutiva crônica? - Google Patents
?novas composições e métodos para o tratamento e/ou prevenção de doença pulmonar obstrutiva crônica?Info
- Publication number
- BR112017016347A2 BR112017016347A2 BR112017016347-0A BR112017016347A BR112017016347A2 BR 112017016347 A2 BR112017016347 A2 BR 112017016347A2 BR 112017016347 A BR112017016347 A BR 112017016347A BR 112017016347 A2 BR112017016347 A2 BR 112017016347A2
- Authority
- BR
- Brazil
- Prior art keywords
- pulmonary disease
- chronic obstructive
- obstructive pulmonary
- prevention
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons
- G01N2333/7158—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons for chemokines
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/12—Pulmonary diseases
- G01N2800/122—Chronic or obstructive airway disorders, e.g. asthma COPD
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/50—Determining the risk of developing a disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Otolaryngology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EPEP15152886.6 | 2015-01-28 | ||
| EP15152886.6A EP3050574B1 (en) | 2015-01-28 | 2015-01-28 | Use of plerixafor for treating and/or preventing acute exacerbations of chronic obstructive pulmonary disease |
| PCT/EP2016/051771 WO2016120369A1 (en) | 2015-01-28 | 2016-01-28 | New compositions and methods of treating and/or preventing chronic obstructive pulmonary disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112017016347A2 true BR112017016347A2 (pt) | 2018-03-27 |
Family
ID=52434596
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112017016347-0A BR112017016347A2 (pt) | 2015-01-28 | 2016-01-28 | ?novas composições e métodos para o tratamento e/ou prevenção de doença pulmonar obstrutiva crônica? |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US10813911B2 (enExample) |
| EP (2) | EP3050574B1 (enExample) |
| JP (1) | JP7127988B2 (enExample) |
| CN (1) | CN107405405B (enExample) |
| AU (1) | AU2016212067B2 (enExample) |
| BR (1) | BR112017016347A2 (enExample) |
| CA (1) | CA2972319C (enExample) |
| DK (1) | DK3050574T3 (enExample) |
| EA (1) | EA201791689A1 (enExample) |
| ES (1) | ES2764840T3 (enExample) |
| IL (1) | IL253688B2 (enExample) |
| WO (1) | WO2016120369A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017127810A1 (en) * | 2016-01-22 | 2017-07-27 | Indiana University Research & Technology Corporation | Methods for repairing lung tissue |
| TWI734027B (zh) * | 2017-09-18 | 2021-07-21 | 泰宗生物科技股份有限公司 | 用於治療癌症之組合物 |
| EP4085910A1 (en) * | 2021-05-05 | 2022-11-09 | 4Living Biotech | Use of a compound such as plerixafor for treating a viral pulmonary disease |
| CN119925562B (zh) * | 2023-11-03 | 2025-11-28 | 中国科学院上海药物研究所 | 趋化因子受体2拮抗剂在制备治疗糖尿病并发焦虑症的应用 |
| KR20250133491A (ko) * | 2024-02-28 | 2025-09-08 | 재단법인 오송첨단의료산업진흥재단 | 인간 ccl7에 결합하는 신규한 항체 및 이의 용도 |
| CN118252937B (zh) * | 2024-04-07 | 2024-10-22 | 中山大学 | Cxcr4受体的拮抗剂在抗埃博拉病毒感染中的应用 |
Family Cites Families (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| US5270163A (en) | 1990-06-11 | 1993-12-14 | University Research Corporation | Methods for identifying nucleic acid ligands |
| US5840867A (en) | 1991-02-21 | 1998-11-24 | Gilead Sciences, Inc. | Aptamer analogs specific for biomolecules |
| GB9126677D0 (en) | 1991-12-16 | 1992-02-12 | Johnson Matthey Plc | Improvements in chemical compounds |
| ATE344324T1 (de) | 1993-09-14 | 2006-11-15 | Imp Innovations Ltd | Eotaxin = eosinophil chemotaktisches cytokin |
| JP3367581B2 (ja) | 1993-10-14 | 2003-01-14 | 小野薬品工業株式会社 | 新規なポリペプチド、その製造方法、そのポリペプチドをコードするｄｎａ、そのｄｎａからなるベクター、そのベクターで形質転換された宿主細胞 |
| US6806061B1 (en) | 1995-01-19 | 2004-10-19 | Children's Medical Center Corporation | G protein-coupled receptor gene and methods of use therefor |
| US6699843B2 (en) | 1995-06-07 | 2004-03-02 | Gilead Sciences, Inc. | Method for treatment of tumors using nucleic acid ligands to PDGF |
| WO1997024325A1 (en) | 1995-12-28 | 1997-07-10 | Takeda Chemical Industries, Ltd. | DIPHENYLMETHANE DERIVATIVES AS MIP-1α/RANTES RECEPTOR ANTAGONISTS |
| EP0914319B1 (en) | 1996-05-20 | 2001-11-21 | Teijin Limited | Diarylalkyl cyclic diamine derivatives as chemokine receptor antagonists |
| AU6133098A (en) | 1997-01-21 | 1998-08-07 | Merck & Co., Inc. | 3,3-disubstituted piperidines as modulators of chemokine receptor activity |
| SK112899A3 (en) | 1997-02-26 | 2001-05-10 | Pfizer | Heteroaryl-hexanoic acid amide derivatives, their preparation and their use as selective inhibitors of mip-1-alpha binding to its ccr1 receptor |
| US6207155B1 (en) | 1997-05-07 | 2001-03-27 | Schering Corporation | Method of eosinophil depletion with antibody to CCR 3 receptor |
| GB9711643D0 (en) | 1997-06-05 | 1997-07-30 | Janssen Pharmaceutica Nv | Glass thermoplastic systems |
| WO1999036518A1 (en) | 1998-01-15 | 1999-07-22 | Btg International Limited | Ribozymal nucleic acids cleaving ccr5 or cxcr4 |
| CA2321962C (en) | 1998-02-27 | 2014-07-15 | The Government Of The United States Of America, Represented By The Secretary Of The Department Of Health And Human Services | G protein-coupled receptor antagonists |
| US6180348B1 (en) | 1998-04-20 | 2001-01-30 | Weihua Li | Method of isolating target specific oligonucleotide ligands |
| CA2235420A1 (en) | 1998-06-17 | 1999-12-17 | Paolo Renzi | Antisense oligonucleotides for treating or preventing atopic diseases and neoplastic cell proliferation |
| US6429308B1 (en) | 1998-11-24 | 2002-08-06 | Hisamitsu Pharmaceutical Co., Inc. | HIV infection inhibitors |
| US6723538B2 (en) | 1999-03-11 | 2004-04-20 | Micromet Ag | Bispecific antibody and chemokine receptor constructs |
| IL145401A0 (en) | 1999-03-24 | 2002-06-30 | Anormed Inc | Chemokine receptor binding heterocyclic compounds |
| AU2001233277B2 (en) | 2000-02-03 | 2004-06-03 | Millennium Pharmaceuticals, Inc. | Humanized anti-ccr2 antibodies and methods of use therefor |
| GB2361704C (en) | 2000-03-03 | 2006-08-02 | Cambridge Antibody Tech | Human antibodies against eotaxin and their use |
| US6946546B2 (en) | 2000-03-06 | 2005-09-20 | Cambridge Antibody Technology Limited | Human antibodies against eotaxin |
| GB0016138D0 (en) | 2000-06-30 | 2000-08-23 | Novartis Ag | Organic compounds |
| US20020147312A1 (en) | 2001-02-02 | 2002-10-10 | O'keefe Theresa | Hybrid antibodies and uses thereof |
| US20050124569A1 (en) | 2001-05-18 | 2005-06-09 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of CXCR4 gene expression using short interfering nucleic acid (siNA) |
| EP2990394A1 (en) | 2001-11-30 | 2016-03-02 | Biogen MA Inc. | Antibodies against monocyte chemotactic proteins |
| AR041786A1 (es) | 2002-03-15 | 2005-06-01 | Novartis Ag | Derivados de azetidina como antagonistas del receptor ccr-3, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos derivados para la elaboracion de un medicamento |
| GB0212357D0 (en) | 2002-05-29 | 2002-07-10 | Glaxo Group Ltd | Novel compounds |
| JP2006502107A (ja) | 2002-07-02 | 2006-01-19 | エフ．ホフマン−ラ ロシュ アーゲー | Ｃｃｒ−３レセプターアンタゴニストｉｘとしての２，５−置換ピリミジン誘導体 |
| US7964194B2 (en) | 2002-11-15 | 2011-06-21 | Morehouse School Of Medicine | Anti-chemokine and associated receptor antibodies and uses for inhibition of inflammation |
| PL378753A1 (pl) | 2003-02-27 | 2006-05-15 | F.Hoffmann-La Roche Ag | Antagoniści receptora CCR-3 |
| US20050069955A1 (en) | 2003-06-30 | 2005-03-31 | Daniel Plaksin | Antibodies and uses thereof |
| AR046594A1 (es) | 2003-10-16 | 2005-12-14 | Applied Research Systems | Usos terapeuticos de variantes de quemoquina |
| AU2005214287A1 (en) | 2004-02-20 | 2005-09-01 | Genesis Research And Development Corporation Limited | Targeted delivery of RNA interference molecules for the treatment of IgE-mediated disorders |
| ATE425161T1 (de) | 2004-05-26 | 2009-03-15 | Janssen Pharmaceutica Nv | Mercaptoimidazole als ccr2-rezeptorantagonisten |
| KR20070063562A (ko) | 2004-09-28 | 2007-06-19 | 얀센 파마슈티카 엔.브이. | 치환 디피페리딘 ｃｃｒ２ 길항제 |
| AU2006203826A1 (en) | 2005-01-07 | 2006-07-13 | Emory University | CXCR4 antagonists for the treatment of HIV infection |
| US7622583B2 (en) | 2005-01-14 | 2009-11-24 | Chemocentryx, Inc. | Heteroaryl sulfonamides and CCR2 |
| TW200716174A (en) | 2005-05-19 | 2007-05-01 | Centocor Inc | Anti-MCP-1 antibodies, compositions, methods and uses |
| GB0517966D0 (en) | 2005-09-02 | 2005-10-12 | Novartis Ag | Organic compounds |
| HUP0500877A2 (en) | 2005-09-22 | 2007-05-29 | Sanofi Aventis | Amide derivatives as ccr3 receptor ligands, process for producing them, pharmaceutical compositions containing them and their use and intermediates |
| EP2041568A4 (en) | 2006-06-15 | 2009-08-12 | CCR2 ANTAGONISTS FOR CHRONIC BREATHING REACTIONS IN ORGAN TRANSPLANTATIONS | |
| ATE537166T1 (de) | 2006-10-27 | 2011-12-15 | Boehringer Ingelheim Int | Piperidylpropanthiole als ccr3-modulatoren |
| HRP20110551T1 (hr) | 2007-05-30 | 2011-09-30 | Eli Lilly & Company | Antagonisti cikličkog peptida cxcr4 |
| CA2692761C (en) | 2007-07-12 | 2013-04-30 | Chemocentryx, Inc. | Fused heteroaryl pyridyl and phenyl benzenesulfonamides as ccr2 modulators for the treament of inflammation |
| EP2237798A2 (en) * | 2007-12-12 | 2010-10-13 | Imperial Innovations Limited | Methods |
| HUP0800478A2 (en) | 2008-07-31 | 2010-03-01 | Sanofi Aventis | Substituted pyrrolidinyl-[1,3]thiazolo[4,5-b]pyridin derivatives as ccr3 receptor ligands |
| WO2010069979A1 (en) | 2008-12-16 | 2010-06-24 | Nycomed Gmbh | Pyran derivatives as ccr3 modulators |
| ES2551557T3 (es) | 2008-12-19 | 2015-11-19 | Boehringer Ingelheim International Gmbh | Pirimidin-4-carboxamidas cíclicas como antagonistas del receptor CCR2 para el tratamiento de inflamaciones, asma y EPOC |
| US8278302B2 (en) | 2009-04-08 | 2012-10-02 | Boehringer Ingelheim International Gmbh | Substituted piperidines as CCR3 antagonists |
| ES2528625T3 (es) | 2009-04-17 | 2015-02-11 | Janssen Pharmaceutica Nv | Antagonistas de 4-azetidinil-1-fenil-ciclohexano de CCR2 |
| US8471004B2 (en) | 2009-10-07 | 2013-06-25 | Hoffman-La Roche Inc. | Bicyclic compounds |
| US8445674B2 (en) | 2009-10-21 | 2013-05-21 | Hoffmann-La Roche Inc | Heterocyclyl compounds |
| JP5356323B2 (ja) * | 2010-07-01 | 2013-12-04 | 富士化学工業株式会社 | 新規な非晶質ボセンタン及びその製造方法 |
| US20120088769A1 (en) * | 2010-10-11 | 2012-04-12 | Axikin Pharmaceuticals, Inc. | Salts of arylsulfonamide ccr3 antagonists |
| EP2646429B1 (en) | 2010-12-01 | 2014-10-15 | Janssen Pharmaceutica NV | 4-substituted-cyclohexylamino-4-piperidinyl-acetamide antagonists of ccr2 |
| US20140005174A1 (en) | 2011-03-17 | 2014-01-02 | Anilkumar G. Nair | Indole derivatives useful as ccr2 antagonists |
| WO2012138880A2 (en) | 2011-04-07 | 2012-10-11 | The Brigham And Women's Hospital, Inc. | Methods of treating inflammatory diseases by targeting the chemoattractant cytokine receptor 2 (ccr2) or chemokine (c-c motif) ligand 2 (ccl2) |
| AU2012258575B2 (en) * | 2011-05-25 | 2017-03-02 | Intermune, Inc. | Pirfenidone and anti-fibrotic therapy in selected patients |
| DK2723360T3 (en) | 2011-06-27 | 2017-08-28 | Univ Pierre Et Marie Curie Paris 6 | CCR2 antagonist peptides |
| US20140336159A1 (en) * | 2011-10-07 | 2014-11-13 | Pulmatrix, Inc. | Methods for treating and diagnosing respiratory tract infections |
| WO2013057545A1 (en) * | 2011-10-18 | 2013-04-25 | Biocon Limited | Acid addition salts of bosentan |
| US8822460B2 (en) | 2012-04-06 | 2014-09-02 | Janssen Pharmaceutica Nv | Fused cyclopentyl antagonists of CCR2 |
| US20160015786A1 (en) * | 2013-03-01 | 2016-01-21 | Mater Medical Research Institute Limited | Mobilizing agents and uses therefor |
| WO2014143807A2 (en) * | 2013-03-15 | 2014-09-18 | Stromatt Scott | Anti-cd37 antibody and bcr pathway antagonist combination therapy for treatment of b-cell malignancies and disorders |
-
2015
- 2015-01-28 DK DK15152886.6T patent/DK3050574T3/da active
- 2015-01-28 ES ES15152886T patent/ES2764840T3/es active Active
- 2015-01-28 EP EP15152886.6A patent/EP3050574B1/en active Active
- 2015-01-28 EP EP19197843.6A patent/EP3613435A1/en not_active Withdrawn
-
2016
- 2016-01-28 CA CA2972319A patent/CA2972319C/en active Active
- 2016-01-28 WO PCT/EP2016/051771 patent/WO2016120369A1/en not_active Ceased
- 2016-01-28 CN CN201680008472.9A patent/CN107405405B/zh active Active
- 2016-01-28 AU AU2016212067A patent/AU2016212067B2/en active Active
- 2016-01-28 EA EA201791689A patent/EA201791689A1/ru unknown
- 2016-01-28 JP JP2017540788A patent/JP7127988B2/ja active Active
- 2016-01-28 BR BR112017016347-0A patent/BR112017016347A2/pt not_active Application Discontinuation
- 2016-01-28 US US15/547,099 patent/US10813911B2/en active Active
-
2017
- 2017-07-27 IL IL253688A patent/IL253688B2/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3050574B1 (en) | 2019-10-09 |
| EA201791689A1 (ru) | 2017-11-30 |
| AU2016212067A1 (en) | 2017-09-14 |
| IL253688A (en) | 2017-09-28 |
| CN107405405A (zh) | 2017-11-28 |
| JP2018505187A (ja) | 2018-02-22 |
| US10813911B2 (en) | 2020-10-27 |
| JP7127988B2 (ja) | 2022-08-30 |
| WO2016120369A1 (en) | 2016-08-04 |
| DK3050574T3 (da) | 2020-01-20 |
| EP3050574A1 (en) | 2016-08-03 |
| AU2016212067B2 (en) | 2020-10-08 |
| US20180271831A1 (en) | 2018-09-27 |
| CA2972319C (en) | 2023-08-01 |
| CN107405405B (zh) | 2021-05-11 |
| IL253688B1 (en) | 2023-01-01 |
| EP3613435A1 (en) | 2020-02-26 |
| ES2764840T3 (es) | 2020-06-04 |
| CA2972319A1 (en) | 2016-08-04 |
| IL253688B2 (en) | 2023-05-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| LT3496739T (lt) | Kompozicijos ir būdai, skirti plaučių hipertenzijai gydyti | |
| BR112016022785A2 (pt) | composto, composição farmacêutica, kit farmacêutico para tratar um câncer, e, métodos de tratamento de uma doença e/ou uma condição e/ou um distúrbio e de síntese de um composto | |
| IL270776A (en) | Cblb endonuclease variants, compositions, and methods of use | |
| EA201891910A1 (ru) | Гетероарильные ингибиторы pad4 | |
| MX389447B (es) | Composiciones y métodos para anticuerpos dirigidos a bmp6. | |
| EA201691134A1 (ru) | Новые ингибиторы глутаминазы | |
| BR112017008714A2 (pt) | inibidores de bromodomínio | |
| LT3600270T (lt) | Junginiai ir kompozicijos hematologiniams sutrikimams gydyti | |
| BR112017025499A2 (pt) | benefícios da suplementação com n-acetil cisteína e glicina para melhorar os níveis de glutationa | |
| BR112017005266A2 (pt) | inibidores de mk2 e uso dos mesmos | |
| PT3377516T (pt) | Composição para o tratamento do cancro | |
| PL3277270T3 (pl) | Kompozycje i sposoby leczenia niedokrwistości | |
| BR112016028891A2 (pt) | processos de trens de sementes e usos dos mesmos | |
| EA201691582A1 (ru) | Новые фармацевтические препараты | |
| EA201891347A1 (ru) | Аза-бензимидазольные ингибиторы pad4 | |
| IL254876A0 (en) | Treatment of lung cancer with inhibitors of glutaminase | |
| BR112016017112A2 (pt) | Composições de apilimod e métodos de uso das mesmas | |
| EP3380062A4 (en) | Compositions for treating the hair | |
| IL255185A0 (en) | 1-heteroaryl-indoline-4-carboxamides as modulators of gpr52 useful for the treatment or prevention of disorders related thereto | |
| BR112018000776A2 (pt) | métodos para tratamento de câncer usando apilimod | |
| BR112017007414A2 (pt) | combinações compreendendo siponimod e laquinimod para o tratamento de esclerose múltipla | |
| BR112018000124A2 (pt) | material para aperfeiçoar atributos de uma composição para tratamento tópico ou de superfície | |
| SI3573620T1 (sl) | Sestavki za zdravljenje hipertenzije | |
| IL253688A (en) | New preparations and methods for the treatment or prevention of chronic obstructive pulmonary diseases | |
| IL269884B1 (en) | Gemcabene, pharmaceutically acceptable salts thereof, compositions thereof and methods of use therefor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] |